ASSOCIATION OF THE NOVEL CACHEXIA MARKER “GROWTH DIFFERENTIATION FACTOR 15” (GDF15) WITH MORTALITY IN HEMODIALYSIS PATIENTS

Kam Kalantar-Zadeh1, Lorena Lerner2, Richard Nicoletti2, Bin Feng2, Melissa Soohoo1, Elani Streja1, Connie M Rhee1, Hamid Moradi1, Jennie Jing1, Tracy Nakata1, Csaba Kovesdy3 and Jeno Gyuris2

1UC Irvine Medical Center, Nephrology and Hypertension, Orange, CA, 2AVEO Oncology, Oncology, Cambridge, MA, 3Univ. Tennessee Health Sciences Center, Nephrology, Memphis, TN

Introduction and Aims: Cachexia and muscle wasting are associated with poor outcomes including decreased survival in dialysis dependent CKD patients. The novel cachexia maker GDF15 is a protein associated with inflammation, cardiovascular disease and higher mortality in several cancer types but its role in CKD is not known.

Methods: We examined the association of GDF15 and all-cause mortality in a cohort of 205 hemodialysis patients enrolled in the Malnutrition, Diet and Racial Disparities in Chronic Kidney Disease (MADRAD) study with follow-up for up to 3 years (2011-2014).

Results: Patients were 53±15 years old and included 40% women, 34% blacks and 57% diabetics. The average (±SD) GDF15 plasma level was 6.0 (±4.0) ng/ml and median was 5.0 ng/ml. There were 21 vs. 8 deaths in patients with GDF15 above vs. below median. Univariate and multivariate (adjusted by age gender and ethnicity) showed a death HR of low vs. high GDF15 of 0.34 (p=0.006) and 0.40 (p=0.038), respectively. Kaplan-Meier survival data are shown:

Conclusions: Hence, higher serum GDF15 levels are associated with substantially higher mortality in hemodialysis patients. Whether modulating GDF15 pathways to correct cachexia improves survival warrants clinical trials.